• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Generic corticosteroid for dogs, cats and horses receives FDA approval

April 5, 2023

Bimasone Injectable Solution is a corticosteroid drug that contains flumethasone in the same concentration and dosage form as Flucort.

Officials with the FDA have approved Bimasone Injectable Solution, the first generic flumethasone, for certain diseases that cause inflammation in horses, dogs, and cats. Sponsored by Bimeda Animal Health, this product is recommended for the various rheumatic, allergic, dermatologic, and other disease states that are known to be responsive to anti-inflammatory drugs (ie, corticoids) in these species.

Bimasone Injectable Solution is a corticosteroid drug that contains the same active ingredient (flumethasone) in the same concentration and dosage form as Flucort, the approved brand name drug product. Flucort was first approved for use in horses, dogs, and cats on October 21, 1965.

In horses, flumethasone is indicated for musculoskeletal conditions caused by inflammation, such as bursitis, carpitis, osselets, and myositis. In cats, flumethasone is indicated for certain acute and chronic skin conditions, from various causes, to help control the associated pruritus, irritation, and inflammation.

In dogs, the drug product is indicated for musculoskeletal conditions caused by inflammation of muscles or joints, such as arthritis, osteoarthritis, intervertebral disc disease, and myositis. The drug has also proven useful in treating canine otitis externa when used with topical medication for similar reasons. It is also approved for certain acute and chronic skin conditions, from various causes, to help control the associated pruritus, irritation, and inflammation, and for use in treating allergic reactions such as hives, urticaria, and insect bites. Flumethasone is also indicated for treating shock in dogs, when administered intravenously, according to the FDA.

Advertisement

Bimasone is supplied in a 0.5mg/mL concentration in 100 mL multi-dose vials. The drug product is only available by prescription from a licensed veterinarian.

Reference

FDA approves first generic flumethasone for certain anti-inflammatory responsive diseases in cats, dogs and horse. News release. FDA. April 5, 2023. Accessed April 5, 2023. https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-flumethasone-certain-anti-inflammatory-responsive-diseases-cats-dogs-and?utm_medium=email&utm_source=govdelivery

Related Content:

FDAPharmacyFeline MedicineEquine Medicine
FDA and European Union expand Mutual Recognition Agreement to include animal drugs
FDA and European Union expand Mutual Recognition Agreement to include animal drugs
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
Combining the best of private practice with clinic spay/neuter care
Combining the best of private practice with clinic spay/neuter care

Advertisement

Latest News

Can our Pride panel answer these LGBTQ+ trivia questions?

Creating inclusive spaces for the LGBTQ+ community in vet med

Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more

CityVet Celina opens in Prosper, Texas

View More Latest News
Advertisement